- List
- By Topic
- On Map
- Search Details

hepatitis delta | Active, not recruiting, Completed, Enrolling by invitation, Suspended, Terminated, Withdrawn, No longer available, Temporarily not available, Approved for marketing, Unknown status Studies | hepatitis D
Need help? See RSS Feeds
Choose a feed type:

hepatitis delta | Active, not recruiting, Completed, Enrolling by invitation, Suspended, Terminated, Withdrawn, No longer available, Temporarily not available, Approved for marketing, Unknown status Studies | hepatitis D (28 records)
Need help? See Downloading Content for Analysis
For Advanced Users: Full Study Record XML Download
1 | NCT01861444 | Terminated | An Observational Study on the Prevalence of Chronic Hepatitis D in Romania and the Efficacy of Treatment With Pegasys (Peginterferon Alfa-2a) |
|
Observational |
|
Industry |
|
|
45 | All | 18 Years and older (Adult, Senior) | NCT01861444 | ML25581 | March 2011 | March 2015 | March 2015 | May 23, 2013 | November 2, 2016 |
|
||||
2 | NCT01495585 | Completed Has Results |
Lonafarnib for Chronic Hepatitis D |
|
|
Interventional | Phase 2 |
|
NIH |
|
|
14 | All | 18 Years and older (Adult, Senior) | NCT01495585 | 120046 12-DK-0046 |
December 2011 | April 2015 | April 2015 | December 20, 2011 | August 31, 2016 | August 31, 2016 |
|
|
3 | NCT02511431 | Completed | Treatment of Chronic Delta Hepatitis With Lonafarnib and Ritonavir |
|
|
Interventional | Phase 2 |
|
NIH |
|
|
22 | All | 18 Years and older (Adult, Senior) | NCT02511431 | 150170 15-DK-0170 |
July 29, 2015 | February 23, 2017 | February 23, 2017 | July 30, 2015 | February 14, 2018 |
|
||
4 | NCT00023322 | Completed Has Results |
Pegylated Interferon to Treat Chronic Hepatitis D |
|
|
Interventional | Phase 2 |
|
NIH |
|
|
13 | All | 18 Years and older (Adult, Senior) | NCT00023322 | 010247 01-DK-0247 |
August 2001 | May 2012 | October 2012 | September 3, 2001 | July 10, 2013 | July 10, 2013 |
|
|
5 | NCT02732639 | Completed Has Results |
A Study of Pegylated Interferon (PEG-IFN) Alfa-2a (Pegasys) in Participants With Chronic Hepatitis D (CHD) |
|
|
Interventional | Phase 3 |
|
Industry |
|
|
31 | All | 18 Years and older (Adult, Senior) | NCT02732639 | ML18788 | October 2005 | December 2008 | December 2008 | April 8, 2016 | August 26, 2016 | August 26, 2016 |
|
|
6 | NCT02765802 | Active, not recruiting | A Study to Evaluate Pegylated Interferon Lambda Monotherapy in Patients With Chronic Hepatitis Delta Virus Infection |
|
|
Interventional | Phase 2 |
|
Industry |
|
|
33 | All | 18 Years to 65 Years (Adult) | NCT02765802 | EIG-LMD-001 | LIMT | October 19, 2016 | June 2018 | December 2018 | May 9, 2016 | July 31, 2017 |
|
|
7 | NCT03105310 | Active, not recruiting | Pegylated Interferon Alone or in Combination With Ezetimibe for Patients With Chronic Hepatitis D |
|
|
Interventional | Phase 2 |
|
Other |
|
|
20 | All | 18 Years and older (Adult, Senior) | NCT03105310 | 3636-Med-ERC | January 2016 | December 2016 | June 2017 | April 7, 2017 | April 7, 2017 | |||
8 | NCT01316185 | Terminated | Proof-of-concept Study Evaluating the Safety and Efficacy of EBP921 in Delta Hepatitis (HDV) |
|
|
Interventional | Phase 1 |
|
Industry |
|
|
3 | All | 18 Years and older (Adult, Senior) | NCT01316185 | EBP-HDV 01-921-01 | January 2011 | April 2013 | April 2013 | March 16, 2011 | August 8, 2016 |
|
||
9 | NCT02731131 | Completed Has Results |
A Study of Peginterferon Alfa-2a With or Without Ribavirin in Participants With Chronic Hepatitis D (CHD) |
|
|
Interventional | Phase 2 |
|
Industry |
|
|
12 | All | 18 Years and older (Adult, Senior) | NCT02731131 | ML18149 | September 2004 | May 2009 | May 2009 | April 7, 2016 | July 15, 2016 | July 15, 2016 |
|
|
10 | NCT02044055 | Completed | Mother-to-child Hepatitis D Transmission |
|
Observational |
|
Other |
|
|
54 | All | 9 Months to 15 Years (Child) | NCT02044055 | Liver004 | October 2014 | April 2017 | April 2017 | January 23, 2014 | April 27, 2017 |
|
||||
11 | NCT00932971 | Completed | HIDIT II - PegIFN-alfa2a Plus Tenofovir in Chronic Delta Hepatitis |
|
|
Interventional | Phase 2 |
|
Other / Industry |
|
|
70 | All | 18 Years and older (Adult, Senior) | NCT00932971 | Hep-Net-HIDIT-II EudraCT-No.: 2008-005560-13 |
HIDIT-II | June 2009 | August 2017 | August 2, 2017 | July 7, 2009 | January 29, 2018 |
|
|
12 | NCT01088659 | Completed | A Study of Pegasys (Peginterferon Alfa 2a) Alone or in Combination With Tenofovir in Patients With Chronic Hepatitis D. |
|
|
Interventional | Phase 3 |
|
Industry |
|
|
50 | All | 18 Years and older (Adult, Senior) | NCT01088659 | ML22364 | February 16, 2010 | December 5, 2017 | December 5, 2017 | March 17, 2010 | January 12, 2018 |
|
||
13 | NCT02637999 | Completed Has Results |
Myrcludex B Plus Pegylated Interferon-alpha-2a in Patients With HBeAg Negative HBV/HDV Co-infection |
|
|
Interventional | Phase 1 Phase 2 |
|
Industry |
|
|
24 | All | 18 Years to 65 Years (Adult) | NCT02637999 | MYR 201 (HDV) | February 13, 2014 | January 21, 2016 | January 21, 2016 | December 22, 2015 | April 13, 2018 | April 13, 2018 | ||
14 | NCT02527707 | Completed | Titrating-Dose of Lonafarnib in Combination With Ritonavir |
|
|
Interventional | Phase 2 |
|
Industry / Other |
|
|
15 | All | 18 Years to 65 Years (Adult) | NCT02527707 | EIG-LNF-002 | LOWR 4 | September 2015 | August 2016 | August 2016 | August 19, 2015 | February 9, 2018 | ||
15 | NCT02430194 | Completed | Lonafarnib With Ritonavir in HDV (LOWR-2) |
|
|
Interventional | Phase 2 |
|
Industry / Other |
|
|
58 | All | 18 Years to 65 Years (Adult) | NCT02430194 | EIG-300-Amendment 3 | LOWR-2 | December 2014 | April 18, 2017 | June 15, 2017 | April 30, 2015 | July 31, 2017 |
|
|
16 | NCT02430181 | Completed | Lonafarnib With and Without Ritonavir in HDV (LOWR-1) |
|
|
Interventional | Phase 2 |
|
Industry |
|
|
21 | All | 18 Years to 65 Years (Adult) | NCT02430181 | EIG-300 Application #1128309 |
LOWR-1 | November 2014 | September 2015 | November 2015 | April 30, 2015 | January 20, 2017 |
|
|
17 | NCT00117533 | Unknown † | Pegylated Interferon Alfa-2b Plus Ribavirin in Chronic Hepatitis B and Delta |
|
|
Interventional | Phase 4 |
|
Other |
|
|
20 | All | 18 Years and older (Adult, Senior) | NCT00117533 | 930904 | September 2005 | June 2007 | July 7, 2005 | May 25, 2006 |
|
|||
18 | NCT02233075 | Completed | REP 2139-Ca / Pegasys™ Combination Therapy in Hepatitis B / Hepatitis D Co-infection |
|
|
Interventional | Phase 2 |
|
Industry |
|
|
12 | All | 18 Years to 55 Years (Adult) | NCT02233075 | REP 301 | September 2014 | November 2016 | May 2017 | September 8, 2014 | September 28, 2017 |
|
||
19 | NCT00005305 | Completed | Hepatitis Delta Infections in Hemophiliacs |
|
|
Observational |
|
Other / NIH | 61 | Male | up to 100 Years (Child, Adult, Senior) | NCT00005305 | 3006 R01HL037974 |
September 1987 | September 1991 | September 1991 | May 26, 2000 | June 14, 2016 | ||||||
20 | NCT02876419 | Active, not recruiting | A Long Term Follow-up Study of Patients From the REP 301 Protocol |
|
Observational |
|
Industry |
|
|
11 | All | 18 Years to 55 Years (Adult) | NCT02876419 | REP 301-LTF | August 2016 | August 2019 | November 2019 | August 23, 2016 | April 11, 2018 |
|
||||
21 | NCT00686790 | Completed Has Results |
Efficacy of Peginterferon Alfa-2b in Previously Untreated Subjects With Chronic Hepatitis B and D Co-infection (Study P04603) |
|
|
Interventional | Phase 3 |
|
Industry |
|
|
68 | All | 18 Years to 65 Years (Adult) | NCT00686790 | P04603 | December 2005 | May 2009 | May 2009 | May 30, 2008 | April 6, 2017 | January 17, 2011 | ||
22 | NCT02259855 | Completed | Pharmacokinetics (PK) of Tipranavir/Ritonavir, Ribavirin, Pegylated Interferon (Peg INF) in Hepatitis C (HCV) Subjects With Mild Hepatic Impairment and in HCV, Hepatitis B (HBV), Hepatitis D Infected Subjects or Alcoholic Cirrhosis With Moderate Hepatic Impairment |
|
|
Interventional | Phase 1 |
|
Industry |
|
|
36 | All | 18 Years to 75 Years (Adult, Senior) | NCT02259855 | 1182.59 | January 2006 | October 2008 | October 9, 2014 | October 9, 2014 | ||||
23 | NCT02577029 | Terminated | Study of ARC-520 With or Without Other Drugs Used in the Treatment of Chronic HBV |
|
|
Interventional | Phase 2 |
|
Industry |
|
|
80 | All | 18 Years to 75 Years (Adult, Senior) | NCT02577029 | Heparc-2008 | Monarch | December 2015 | December 2016 | December 2016 | October 15, 2015 | January 19, 2017 |
|
|
24 | NCT00005304 | Completed | Delta Hepatitis and Liver Disease in Hemophiliacs |
|
Observational |
|
Other / NIH | Male | up to 100 Years (Child, Adult, Senior) | NCT00005304 | 3005 R01HL037951 |
September 1986 | September 1991 | May 26, 2000 | December 10, 2015 | |||||||||
25 | NCT00001457 | Completed | Lamivudine for Chronic Hepatitis B |
|
|
Interventional | Phase 2 |
|
NIH |
|
60 | All | Child, Adult, Senior | NCT00001457 | 950199 95-DK-0199 |
September 1995 | September 2005 | November 4, 1999 | March 4, 2008 |
|
||||
26 | NCT01706575 | Completed Has Results |
A Study of Pegasys (Peginterferon Alfa-2a) Added to Nucleos(t)Ide Analogue Treatment in Participants With HBeAg-Negative Chronic Hepatitis B Genotype D Showing Stable Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) Suppression |
|
|
Interventional | Phase 2 |
|
Industry |
|
|
76 | All | 18 Years to 65 Years (Adult) | NCT01706575 | ML28262 2012-000080-25 |
January 2013 | September 2013 | November 2014 | October 15, 2012 | February 20, 2017 | August 5, 2016 |
|
|
27 | NCT00239733 | Terminated Has Results |
Anti-D for Treating Thrombocytopenia in Adults Infected With Hepatitis C Virus With or Without HIV Co-Infection |
|
|
Interventional | Phase 4 |
|
NIH |
|
|
6 | All | 18 Years and older (Adult, Senior) | NCT00239733 | K23AI065319-01 | March 2005 | February 2010 | February 2010 | October 17, 2005 | May 16, 2017 | May 16, 2017 |
|
|
28 | NCT01226446 | Completed | Efficacy of Vitamin D on Top of Pegylated Interferon and Ribavirin in Patients With Chronic Viral Hepatitis C Null-Responders |
|
|
Interventional | Phase 2 |
|
Other |
|
|
32 | All | 18 Years and older (Adult, Senior) | NCT01226446 | 2010-021967-34 | ANRS VITAVIC | November 2010 | February 2012 | January 2013 | October 22, 2010 | August 11, 2014 |
|
† Study has passed its completion date and status has not been verified in more than two years.